Role Of Cisplatin And Cyclophosphamide Chemotherapy In Bulky Residual Disease After Primary Cytoreductive Surgery Of Epithelial Ovarian Cancers.

Role Of Cisplatin And Cyclophosphamide Chemotherapy In Bulky Residual Disease After Primary Cytoreductive Surgery Of Epithelial Ovarian Cancers.

Authors

  • SHAHARYAR .
  • Z ALAUDDIN
  • Z FARUQUI
  • M HUSSAIN
  • N MANZOOR
  • Z RASOOL
  • A J HUSSAIN

DOI:

https://doi.org/10.21649/akemu.v4i1.3762

Keywords:

Cytoreduction surgery, chemotherapy, and ovarian tumour.

Abstract

From May 1993 to June 1997, 58 patients with bulky residual disease after primary cytoreductive surgery of epithelial ovarian cancer were treated with cisplatin and cyclophosphamide combination chemotherapy. Overall responses were seen in 30 patients (51.72%) with complete responses in 9 patients (15.51%) and partial responses in 21 patients (36.11%) at 4 months. 28 patients (48.27%) were non-responders. Response in relation to the size of residual disease revealed that 24 out of 36 patients (66.66%) did not show a complete response to chemotherapy. It is concluded that bulky residual disease of greater than 4 cm responds poorly to cisplatin and cyclophosphamide combination chemotherapy.

Downloads

Published

08/11/2020

How to Cite

., S., ALAUDDIN, Z. ., FARUQUI, Z. ., HUSSAIN, M. ., MANZOOR, N. ., RASOOL, Z. ., & HUSSAIN, A. J. . (2020). Role Of Cisplatin And Cyclophosphamide Chemotherapy In Bulky Residual Disease After Primary Cytoreductive Surgery Of Epithelial Ovarian Cancers. Annals of King Edward Medical University, 4(1), 13–15. https://doi.org/10.21649/akemu.v4i1.3762

Issue

Section

Research Articles

Similar Articles

> >> 

You may also start an advanced similarity search for this article.

Loading...